Evolus vs MannKind
MannKind reported revenue of $349 million in fiscal 2025, 1.2 times Evolus' $297 million in fiscal 2025. Evolus' revenue grew 11.6% in its latest year, and MannKind's grew 22.2%. Evolus had an operating margin of -11.0%, against 11.1% at MannKind. Free cash flow was −$46 million at Evolus and $14 million at MannKind.
Side by side
| Evolus | MannKind | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $297M | $349M |
| Revenue growth | 11.6% | 22.2% |
| Revenue growth a year, last 5 years | 39.4% | 39.9% |
| Gross margin | 66.3% | 92.3% |
| Operating margin | −11.0% | 11.1% |
| Net margin | −17.4% | 1.7% |
| Free cash flow | −$46M | $14M |
| Free cash flow margin | −15.4% | 3.9% |
| Return on capital | −47.2% | — |
| Net debt to EBITDA | — | 3.6x |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 4.0% | 10.7% |
| Last close | $6.96 | $4.13 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | 2 of 9 | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
EvolusMannKind
Operating margin
Percent of revenue
EvolusMannKind
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
EvolusMannKind